focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,168.00
Ask: 12,170.00
Change: -74.00 (-0.60%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ireland Eyes Vaccines For All Adults By September Despite Supply Fears

Tue, 26th Jan 2021 16:10

(Alliance News) - Ireland's target remains to vaccinate every adult in the country by September, despite disruptions to the supply chain, the upper house of the country's legislature, has heard.

Junior Minister Anne Rabbitte, speaking on behalf of the Health Minister, said the Irish government has "significant concerns" that one vaccine producer, AstraZeneca PLC, will be unable to meet its initial delivery commitments.

This has led to some "adjustments" to the government's target of vaccinating 700,000 people by the end of March, Rabbitte said.

The goal of vaccinating all adults by September remains the target, but it is contingent on steady flow of vaccines.

Rabbitte said: "The minister for health previously stated that he expected all adult residents to be vaccinated by September.

"That remains our target.

"However, as Minister Donnelly stressed, it is contingent on existing commitments on the approval, supply and delivery of vaccines."

The AstraZeneca vaccine is crucial to the government's planned vaccine delivery schedule.

It is scheduled for approval by the European Medicines Agency on Friday, but the company recently announced it will initially supply considerably fewer doses than agreed with the EU.

The announcement has caused outrage in the EU, which pre-financed the production and delivery of the vaccine.

The new delivery schedule is "not acceptable", European Health Commissioner Stella Kyriakides has warned the company.

On Tuesday, Rabbitte also criticised the company over the delays.

She said: "Of significant concern is the recent indication that AstraZeneca will not be available to meet its initial delivery commitments.

"It is estimated that deliveries in February will be at the low range of what was anticipated, and there will be further significant impact in March.

"The Department of Health is monitoring this change of situation, and is continually engaging with the commission and the company.

"The minister is very concerned that this supply issue was only communicated to the member states just a week before the scheduled authorisation was to be given for the vaccine."

Rabbitte also warned that the arrival of the vaccines and the prospect of a return to normality "gives rise to public expectation that cannot be met in the short term".

The EU had expected to receive 100 million doses of the AstraZeneca vaccine in the first quarter of the year.

It is now feared it will receive only half that amount.

Brussels has threatened to block exports of Covid-19 vaccines outside of the bloc as a result of the ongoing row.

As of Sunday, the HSE has administered 143,000 vaccine doses in Ireland.

Two doses delivered three or four weeks apart are required for the vaccines currently in use in Ireland, Pfizer Inc/BioNTech SE and Moderna Inc.

The HSE began administration of the second doses of the vaccine last week.

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.